Overview

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation. The study medication will be used as a treatment against partial epilepsy.
Phase:
Phase 3
Details
Lead Sponsor:
Desitin Arzneimittel GmbH
Collaborator:
FGK Clinical Research GmbH
Treatments:
Carbamazepine
Oxcarbazepine